The feasibility of home monitoring of young people with cystic fibrosis: Results from CLIMB-CF
- PMID: 34635459
- DOI: 10.1016/j.jcf.2021.09.018
The feasibility of home monitoring of young people with cystic fibrosis: Results from CLIMB-CF
Abstract
Background: CF is traditionally assessed in clinic. It is unclear if home monitoring of young people with CF is feasible or acceptable. The COVID-19 pandemic has made home monitoring more of a necessity. We report the results of CLIMB-CF, exploring home monitoring's feasibility and potential obstacles.
Methods: We designed a mobile app and enrolled participants with CF aged 2-17 years and their parents for six months. They were asked to complete a variety of measures either daily or twice a week. During the study, participants and their parents completed questionnaires exploring depression, anxiety and quality of life. At the end of the study parents and participants completed acceptability questionnaires.
Results: 148 participants were recruited, 4 withdrew prior to starting the study. 82 participants were female with median (IQR) age 7.9 (5.2-12 years). Median data completeness was 40.1% (13.6-69.9%) for the whole cohort; when assessed by age participants aged ≥ 12 years contributed significantly less (15.6% [9.8-30%]). Data completeness decreased over time. There was no significant difference between parental depression and anxiety scores at the start and the end of the study nor in CFQ-R respiratory domain scores for participants ≥ 14 years. The majority of participants did not feel the introduction of home monitoring impacted their daily lives.
Conclusions: Most participants felt home monitoring did not negatively impact their lives and it did not increase depression, anxiety or decrease quality of life. However, uptake was variable, and not well sustained. The teenage years pose a particular challenge and further work is required.
Keywords: Anxiety; Depression; Digital technology; Feasibility; Home monitoring.
Copyright © 2021. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest No declarations of interested related to this paper DMC reports not related to this work honorarium from Vertex pharmaceuticals JM reports not related to this work participation on advisory boards for Vertex pharmaceuticals MB reports not related to this work Investigator led research grants from Pfizer and Roche Diagnostics. Institutional fees from Roche Diagnostics and TEVA. Travel expenses from Boehringer Ingelheim and Vertex pharmaceuticals. JCD reports not related to this work institutional fees from Vertex pharmaceuticals, AbbVie, Boehringer Inglehaim, Arcturus Therapeutics, Algipharma. Individual fees Eloxx Pharmaceuticals and Gilead Science inc.
Comment in
-
Home monitoring for cystic fibrosis: The future is now.J Cyst Fibros. 2022 Jan;21(1):15-17. doi: 10.1016/j.jcf.2021.12.005. Epub 2021 Dec 11. J Cyst Fibros. 2022. PMID: 34906432 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical